Conflict of interest: none declared.
Clinical dermatology •Original article
The role of inflammatory markers in assessing disease severity and response to treatment in patients with psoriasis treated with etanercept
Article first published online: 25 JUL 2011
© The Author(s). CED © 2011 British Association of Dermatologists
Clinical and Experimental Dermatology
Volume 36, Issue 8, pages 845–850, December 2011
How to Cite
Kanelleas, A., Liapi, C., Katoulis, A., Stavropoulos, P., Avgerinou, G., Georgala, S., Economopoulos, T., Stavrianeas, N. G. and Katsambas, A. (2011), The role of inflammatory markers in assessing disease severity and response to treatment in patients with psoriasis treated with etanercept. Clinical and Experimental Dermatology, 36: 845–850. doi: 10.1111/j.1365-2230.2011.04131.x
- Issue published online: 10 NOV 2011
- Article first published online: 25 JUL 2011
- Accepted for publication 20 March 2011
Background. Psoriasis is a chronic, systemic, inflammatory disease. Inflammatory markers are used in clinical practice to detect acute inflammation, and as markers of treatment response. Etanercept blocks tumour necrosis factor (TNF)-α, which plays a central role in the psoriatic inflammation process.
Aim. To reveal any possible association between disease severity [measured by Psoriasis Area and Severity Index (PASI)] and the inflammatory burden (measured by a group of inflammatory markers), before and after etanercept treatment.
Methods. In total, 41 patients with psoriasis vulgaris, eligible for biological treatment with etanercept, were enrolled in the study. A set of inflammatory markers was measured, including levels of white blood cells and neutrophils, fibrinogen, ferritin, high-sensitivity C-reactive protein (hs-CRP), erythrocyte sedimentation rate (ESR), haptoglobin, ceruloplasmin and α1-antitrypsin, before and after 12 weeks of etanercept 50 mg twice weekly.
Results. All markers were reduced after treatment (P < 0.001). PASI correlated with fibrinogen and hs-CRP. Of the 41 patients, 19 (46.3%) achieved reduction of 75% in PASI (PASI75). An increase in hs-CRP and ESR difference (values before minus values after treatment) was related to higher likelihood of achieving PASI75.
Conclusions. Inflammatory markers, particularly hs-CRP and to a lesser extent, fibrinogen and ESR, can be used to assist in assessing disease severity and response to treatment in patients with psoriasis. A combination of selected inflammatory factors (which we term the Index of Psoriasis Inflammation) in combination with PASI might reflect inflammatory status in psoriasis more accurately than each one separately.